Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: Cost-effectiveness analysis

Voprosy Onkologii

Volumn 61, Issue 4, 2015, Pages 676-680

  Protsenko, S A ^a   Rudakova, A V ^b  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b ST PETERSBURG STATE CHEMICAL PHARMACEUTICAL ACADEMY   (Russian Federation)

Author keywords

Afatinib; Cell; Cost effectiveness analysis; Erlotinib; Gefitinib; Lung cancer; Non small

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; AFATINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; ERLOTINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER PATIENT; COST EFFECTIVENESS ANALYSIS; HUMAN; NON SMALL CELL LUNG CANCER; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; ECONOMICS; EXON; GENE DELETION; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; POINT MUTATION; QUALITY OF LIFE; RETROSPECTIVE STUDY; RUSSIAN FEDERATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG COSTS; ERLOTINIB HYDROCHLORIDE; EXONS; GENE DELETION; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RUSSIA; TREATMENT OUTCOME;

EID: 84964964192     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Besse B., Adjei A., Baas P. et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease//Annals of Oncology® - 2014. - Vol. 25. - P. 1475-1484.
2. Cadranel J., Mauguen A., Faller M. et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-part 2)//J. Thorac. Oncol. - 2012. - Vol. 7. - P. 1490-1502.
3. Chabot I., Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma//Value Health. - - Vol. 13 (6). - P. 837-845.
4. Chaft J.E., Oxnard G.R., Sima C.S. et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design//Clin. Cancer Res. - 2011. - Vol. 17. - P. 6298-6303.
5. Fukuoka M., Wu Y-L., Thongprasert S. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)//J. Clin. Oncol. - 2011. - Vol. 29. - P. 2866 - 2874.
6. Han J.Y, Park K., Kim S.W. et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung//J. Clin. Oncol. - 2012. - Vol. 30. - P. 1122- 1128.
7. Horgan A., Bradbury P., Amir E. et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer//Ann. Oncol. - - Vol. 22. - P. 1805 - 1811.
8. Jiang J., Huang L., Liang X. et al. Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials.//Acta Oncol. - 2011. - Vol. 50 (4). - P. 582-588.
9. Jnsson B. Technology Assessment for New Oncology Drugs//Clin. Cancer Res. - 2013. - Vol. 19. - P. 6-11.
10. Katakami N., Morita S., Yoshioka H. et al. Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advancedlung adenocarcinoma (LA): WJOG 5108L//J Clin. Oncol. - 2014 ASCO Annual Meeting Abstracts. Vol 32, No 15-suppl (May 20 Supplement), 2014: 8041.
11. Keedy V.L., Temin S., Somerfield M.R. et al. American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced nonsmall-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy//J. Clin. Oncol. - 2011. - Vol. 29. - P. 2121-2127.
12. Kerr K., Bubendorf L., Edelman M. et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer//Ann. Oncol. - 2014. - Vol. 25. - P. 1681-1690.
13. Kim S., Uhma J., Leea J. et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non- small cell lung cancer who failed previous chemotherapy//Lung Cancer. - 2012. - Vol. 75. - P. 82- 88.
14. Lee C.K., Brown C., Gralla R.J. et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression- free and overall survival: A meta-analysis//J. Natl. Cancer Inst. - 2013. - Vol. 105. - P. 595-605.
15. Maemondo M., Inoue A., Kobayashi K. et al. Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR//N. Engl. J. Med. - 2010. - Vol. 362. - P. 2380-2388.
16. Malin J. Wrestling with the high price of cancer care: should we control costs by Individuals' ability to pay or society's willingness to pay?//J. Clin. Oncol. - 2010. - Vol. 28. - P. 3212 - 3214.
17. Miller V.A., Hirsh V., Cadranel J. et al. Afatinib versus placebo for patients with advanced, metastatic non- small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial//Lancet Oncol. - 2012. - Vol. 13. - P. 528-538.
18. Mitsudomi T., Kosaka T., Endoh H. et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non- small-cell lung cancer with postoperative recurrence//J. Clin. Oncol. - 2005. - Vol. 23. - P. 2513-2520.
19. Mitsudomi T., Morita S., Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial//Lancet Oncol. - 2010. - Vol. 11. - P. 121-128.
20. Mok T.S., Wu YL., Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma//N. Engl. J. Med. - 2009. - Vol. 361. - P. 947-957.
21. Petrelli N., Winer E., Brahmer J. et al. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening-A Report From the American Society of Clinical Oncology//J. Clin. Oncol. - 2009. - Vol. 27. - P. 6052 - 6069.
22. Rocchi A., Menon D., Verma S., Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: To lambda and beyond//Value Health. - 2008. - Vol. 11 (4). - P. 771 - 783.
23. Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomized phase 3 trial//Lancet Oncol. - 2012. - Vol. 13. - P. 239-246.
24. Rosell R., Moran T., Queralt C. et al. Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer//N. Engl. J. Med. - 2009. - Vol. 361. - P. 958-967.
25. Sequist L., Chih-Hsin Yang J., Yamamoto N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations//J. Clin. Oncol. - 2013. - Vol. 31. - P. 3327 - 3334.
26. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer//Nat. Rev. Cancer. - 2007. - Vol. 7. - P. 169-181.
27. Takano T., Ohe Y, Sakamoto H. et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer//J. Clin. Oncol. - 2005. - Vol. 23. - P. 6829 -6837.
28. Watanabe S., Tanaka J., Ota T. et al. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non- small cell lung cancer patients who benefited from prior effective gefitinib therapy: A retrospective analysis//BMC Cancer. -2011. - Vol. 11. - P. 1.
29. World Health Organization. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization; 2001.
30. Yang J., Schuler M., Yamamoto N. et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations//ASCO Meeting Abstracts, - Jun 2012. - Vol. 30. -P. LBA7500.
31. Zhou C., Wu Y-L., Chen G. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open- label, randomised, phase 3 study//Lancet Oncol. -2011. - Vol. 12. - P. 735-742.